Matches in SemOpenAlex for { <https://semopenalex.org/work/W2107661082> ?p ?o ?g. }
- W2107661082 endingPage "1355" @default.
- W2107661082 startingPage "1347" @default.
- W2107661082 abstract "BackgroundCHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) is accepted as the best available standard treatment for first-line chemotherapy in aggressive non-Hodgkin’s lymphoma (NHL). However, the therapeutic efficacy of CHOP remains unsatisfactory, particularly in high-intermediate risk and high risk patients, and a new strategy is warranted in this patient population. The aim of the present study was to explore a suitable therapeutic-intensified regimen for the treatment of aggressive NHL.Patients and methodsBetween May 1995 and July 1998, a total of 70 patients with high-intermediate risk or high risk aggressive NHL, according to the International Prognostic Index, were enrolled and randomly assigned to receive either eight cycles of standard CHOP (cyclophosphamide 750 mg/m2, doxorubicin 50 mg/m2, vincristine 1.4 mg/m2 and prednisolone 100 mg for 5 days) every 2 weeks, or six cycles of dose-escalated CHOP (cyclophosphamide 1,500 mg/m2, doxorubicin 70 mg/m2, vincristine 1.4 mg/m2 and prednisolone 100 mg for 5 days) every 3 weeks. Lenograstim (glycosylated rHuG-CSF), at a dose of 2 µg/kg/day s.c., was administered daily from day 3 until day 13 with biweekly CHOP and until day 20 with the dose-escalated CHOP. The primary endpoint was complete response rate.ResultsThe complete response rate was 60% [21 of 35; 95% confidence interval (CI) 42% to 76%] with biweekly CHOP and 51% (18 of 35; 95% CI 34% to 69%) with dose-escalated CHOP. The major toxicity was grade 4 neutropenia and was more frequent in the dose-escalated CHOP arm (86%) than in the biweekly CHOP arm (50%). Grade 4 thrombocytopenia was also more frequent in the dose-escalated CHOP arm (20%) than the biweekly CHOP arm (3%). Non-hematological toxicities were acceptable in both arms. One treatment-related death (due to cardiac arrhythmia) was observed in a dose-escalated CHOP patient. Progression-free survival at 3 years was 43% (95% CI 27% to 59%) in the biweekly CHOP arm and 31% (95% CI 16% to 47%) in the dose-escalated CHOP arm. Although seven patients were deemed ineligible by central review of the pathological diagnosis, the results for both eligible and all enrolled patients were similar.ConclusionsSimilar complete response rates and progression-free survival rates, but lower toxicity, indicated that biweekly CHOP was superior to dose-escalated CHOP in the treatment of aggressive NHL. Based on these results, the Lymphoma Study Group of the Japan Clinical Oncology Group is conducting a randomized phase III study comparing biweekly CHOP with standard CHOP in newly diagnosed patients with advanced-stage aggressive NHL." @default.
- W2107661082 created "2016-06-24" @default.
- W2107661082 creator A5000985713 @default.
- W2107661082 creator A5002493998 @default.
- W2107661082 creator A5005771790 @default.
- W2107661082 creator A5006468691 @default.
- W2107661082 creator A5015509689 @default.
- W2107661082 creator A5026553349 @default.
- W2107661082 creator A5026907664 @default.
- W2107661082 creator A5028457340 @default.
- W2107661082 creator A5036000764 @default.
- W2107661082 creator A5048239701 @default.
- W2107661082 creator A5050494732 @default.
- W2107661082 creator A5052084624 @default.
- W2107661082 creator A5052245959 @default.
- W2107661082 creator A5053647194 @default.
- W2107661082 creator A5057175176 @default.
- W2107661082 creator A5065894192 @default.
- W2107661082 creator A5070304401 @default.
- W2107661082 creator A5072163593 @default.
- W2107661082 creator A5074998675 @default.
- W2107661082 date "2002-09-01" @default.
- W2107661082 modified "2023-10-16" @default.
- W2107661082 title "Randomized phase II study of biweekly CHOP anddose-escalated CHOP with prophylactic use of lenograstim (glycosylated G-CSF) in aggressive non-Hodgkin’s lymphoma: Japan Clinical Oncology Group Study 9505" @default.
- W2107661082 cites W1544519462 @default.
- W2107661082 cites W1901299664 @default.
- W2107661082 cites W1905145727 @default.
- W2107661082 cites W1933587402 @default.
- W2107661082 cites W1946151534 @default.
- W2107661082 cites W1958341727 @default.
- W2107661082 cites W1982634085 @default.
- W2107661082 cites W1983167663 @default.
- W2107661082 cites W1997353354 @default.
- W2107661082 cites W2054346828 @default.
- W2107661082 cites W2058015212 @default.
- W2107661082 cites W2071813692 @default.
- W2107661082 cites W2084328794 @default.
- W2107661082 cites W2096105848 @default.
- W2107661082 cites W2096470130 @default.
- W2107661082 cites W2104435282 @default.
- W2107661082 cites W2110562475 @default.
- W2107661082 cites W2117291755 @default.
- W2107661082 cites W2122630078 @default.
- W2107661082 cites W2133720850 @default.
- W2107661082 cites W2142334769 @default.
- W2107661082 cites W2144843163 @default.
- W2107661082 cites W2149038070 @default.
- W2107661082 cites W2150281255 @default.
- W2107661082 cites W2152474929 @default.
- W2107661082 cites W2318772898 @default.
- W2107661082 cites W2334996101 @default.
- W2107661082 cites W2336768886 @default.
- W2107661082 cites W2338377114 @default.
- W2107661082 cites W2339293928 @default.
- W2107661082 cites W2440995134 @default.
- W2107661082 cites W3024436806 @default.
- W2107661082 cites W4205736005 @default.
- W2107661082 doi "https://doi.org/10.1093/annonc/mdf287" @default.
- W2107661082 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12196359" @default.
- W2107661082 hasPublicationYear "2002" @default.
- W2107661082 type Work @default.
- W2107661082 sameAs 2107661082 @default.
- W2107661082 citedByCount "51" @default.
- W2107661082 countsByYear W21076610822012 @default.
- W2107661082 countsByYear W21076610822013 @default.
- W2107661082 countsByYear W21076610822014 @default.
- W2107661082 countsByYear W21076610822015 @default.
- W2107661082 countsByYear W21076610822016 @default.
- W2107661082 countsByYear W21076610822018 @default.
- W2107661082 countsByYear W21076610822019 @default.
- W2107661082 countsByYear W21076610822020 @default.
- W2107661082 countsByYear W21076610822021 @default.
- W2107661082 crossrefType "journal-article" @default.
- W2107661082 hasAuthorship W2107661082A5000985713 @default.
- W2107661082 hasAuthorship W2107661082A5002493998 @default.
- W2107661082 hasAuthorship W2107661082A5005771790 @default.
- W2107661082 hasAuthorship W2107661082A5006468691 @default.
- W2107661082 hasAuthorship W2107661082A5015509689 @default.
- W2107661082 hasAuthorship W2107661082A5026553349 @default.
- W2107661082 hasAuthorship W2107661082A5026907664 @default.
- W2107661082 hasAuthorship W2107661082A5028457340 @default.
- W2107661082 hasAuthorship W2107661082A5036000764 @default.
- W2107661082 hasAuthorship W2107661082A5048239701 @default.
- W2107661082 hasAuthorship W2107661082A5050494732 @default.
- W2107661082 hasAuthorship W2107661082A5052084624 @default.
- W2107661082 hasAuthorship W2107661082A5052245959 @default.
- W2107661082 hasAuthorship W2107661082A5053647194 @default.
- W2107661082 hasAuthorship W2107661082A5057175176 @default.
- W2107661082 hasAuthorship W2107661082A5065894192 @default.
- W2107661082 hasAuthorship W2107661082A5070304401 @default.
- W2107661082 hasAuthorship W2107661082A5072163593 @default.
- W2107661082 hasAuthorship W2107661082A5074998675 @default.
- W2107661082 hasBestOaLocation W21076610821 @default.
- W2107661082 hasConcept C126322002 @default.
- W2107661082 hasConcept C141071460 @default.
- W2107661082 hasConcept C2776694085 @default.
- W2107661082 hasConcept C2776715498 @default.
- W2107661082 hasConcept C2776755627 @default.